Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer.


PURPOSE Panitumumab, a fully human antibody against the epidermal growth factor receptor (EGFR), has activity in a subset of patients with metastatic colorectal cancer (mCRC). Although activating mutations in KRAS, a small G-protein downstream of EGFR, correlate with poor response to anti-EGFR antibodies in mCRC, their role as a selection marker has not… (More)
DOI: 10.1200/JCO.2007.14.7116


7 Figures and Tables